| Property | Value |
|---|
|
?:abstract
|
-
Vaccination is an established but uncommon cause of unilateral axillary lymphadenopathy. Early clinical experience with coronavirus disease (COVID-19) vaccination suggests that the approved COVID-19 vaccines cause a notably higher incidence of axillary lymphadenopathy on breast MRI compared to other vaccines. Guidelines are needed to appropriately manage MRI-detected unilateral axillary lymphadenopathy in the era of COVID-19 vaccination and to avoid biopsies of benign reactive nodes. This article examines the available data on vaccine-related lymphadenopathy and offers a basic strategy to assess axillary lymphadenopathy on MRI and to guide management. At our institution, we are adding questions regarding the date(s) and laterality of administration of COVID-19 vaccination to our intake form before all breast imaging examinations. We consider MRI-detected isolated unilateral axillary lymphadenopathy ipsilateral to the vaccination arm to be most likely COVID-19 vaccine-related if within four weeks of either dose. In these cases, we assess the lymphadenopathy as BI-RADS 3 and recommend a follow-up ultrasound be performed within 6-8 weeks after the second dose. These guidelines may be refined as we gain further data on the expected time-course of axillary lymphadenopathy post COVID-19 vaccination. Until that time, this management pathway will help avoid unnecessary biopsies of benign vaccine-related reactive lymphadenopathy.
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
AJR._American_journal_of_roentgenology
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}